Literature DB >> 30723979

The role of organ- and function-preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx.

Sati Akbaba1,2,3, Kristin Lang1,2,3, Olcay Cem Bulut4, Thomas Held1,2,3, Stefan Rieken1,2,3, Peter Plinkert4, Alexandra Jensen5, Klaus Herfarth1,2,3, Juergen Debus1,2,3, Sebastian Adeberg1,2,3.   

Abstract

BACKGROUND: To evaluate clinical outcome and functional larynx preservation after radiotherapy (RT) for adenoid cystic carcinoma (ACC) of the larynx.
METHODS: Eleven patients with primary ACC of the larynx, who received RT definitely (n = 5/11) or postoperatively (n = 6/11), were analyzed regarding survival and treatment-related toxicity with the focus on functional larynx preservation.
RESULTS: Median follow-up was 45 months. RT offered an excellent 5-year local control (LC) rate of 100%. Eight of 11 patients were treated with a laryngeal preservation approach (LPA). At last follow-up, only one of these eight patients developed a local recurrence requiring a total laryngectomy 11 years after treatment. Severe toxicity was uncommon, with only one patient with LPA, requiring a temporary tracheostomy during therapy.
CONCLUSIONS: RT is an effective treatment method for laryngeal ACC with excellent LC rates, preservation of the laryngeal function and voice formation, representing a valuable therapy alternative to total laryngectomy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  ACC; carbon ion; intensity modulated radiotherapy; larynx; larynx preservation

Mesh:

Year:  2019        PMID: 30723979     DOI: 10.1002/hed.25678

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma.

Authors:  Sebastian Adeberg; Paul Windisch; Felix Ehret; Melissa Baur; Sati Akbaba; Thomas Held; Denise Bernhardt; Matthias F Haefner; Juergen Krauss; Steffen Kargus; Christian Freudlsperger; Peter Plinkert; Christa Flechtenmacher; Klaus Herfarth; Juergen Debus; Stefan Rieken
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.